Apyx Medical Corp. (APYX)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 719135 · fiscal year ends in Dec
Closing price $2.57 on 30 Oct 2026; 52-week range $2.38 to $4.86.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $58.4M
- Revenue growth
- 25.6%
- Net income, last twelve months
- -$8.6M
- Earnings per share
- -$0.20
- Gross margin
- 63.5%
- Operating margin
- -6.1%
- Net margin
- -14.8%
- Free cash flow
- -$11.0M
- Return on equity
- -81.0%
- Market value
- $108.2M
- Cash
- $27.6M
- Debt
- $37.5M
- Debt to equity
- 3.52
- Shares outstanding
- 42.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $52.8M | -$6.4M | -$11.2M | -$0.27 | -$9.1M | 10-K filed 10 Mar 2026 |
| FY2024 | 31 Dec 2024 | $48.1M | -$18.8M | -$23.5M | -$0.66 | -$18.8M | 10-K filed 13 Mar 2025 |
| FY2023 | 31 Dec 2023 | $52.3M | -$17.3M | -$18.7M | -$0.54 | -$5.8M | 10-K filed 21 Mar 2024 |
| FY2022 | 31 Dec 2022 | $44.5M | -$23.6M | -$23.2M | -$0.67 | -$21.3M | 10-K filed 16 Mar 2023 |
| FY2021 | 31 Dec 2021 | $48.5M | -$14.4M | -$15.2M | -$0.44 | -$11.2M | 10-K filed 17 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $13.9M | -$3.2M | -$0.07 |
| Q1 FY2026 | 31 Mar 2026 | $12.5M | -$2.1M | -$0.05 |
| Q4 FY2025 | 31 Dec 2025 | $19.2M | -$1.3M | -$0.03 |
| Q3 FY2025 | 30 Sep 2025 | $12.9M | -$2.0M | -$0.05 |
| Q2 FY2025 | 30 Jun 2025 | $11.4M | -$3.8M | -$0.09 |
| Q1 FY2025 | 31 Mar 2025 | $9.4M | -$4.2M | -$0.10 |
| Q4 FY2024 | 31 Dec 2024 | $14.2M | -$4.6M | -$0.12 |
| Q3 FY2024 | 30 Sep 2024 | $11.5M | -$4.7M | -$0.14 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Surgical Aesthetics | $45.3M | 85.8% |
| OEM | $7.5M | 14.2% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $38.8M | 73.4% |
| Non-US | $14.0M | 26.6% |
Company events
The newest 8-K filings of 185 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 29 Sep 2026 | 8-K | Other events | 8.01, 9.01 |
| 7 Aug 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 24 Jul 2026 | 8-K | Other events | 8.01, 9.01 |
| 17 Jun 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 21 May 2026 | 8-K | Other events | 8.01, 9.01 |
| 14 May 2026 | 8-K | Other events | 8.01, 9.01 |
| 11 May 2026 | 8-K | Other events | 8.01, 9.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 10 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Dec 2025 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
Every filing
The newest filings with the SEC of 503 held.
| Filed | Form | Period |
|---|---|---|
| 29 Sep 2026 | 8-K | 29 Sep 2026 |
| 7 Aug 2026 | 8-K | 6 Aug 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 24 Jul 2026 | 8-K | 24 Jul 2026 |
| 26 Jun 2026 | DEF 14A | 31 Dec 2025 |
| 17 Jun 2026 | 8-K | 11 Jun 2026 |
| 1 Jun 2026 | SD | – |
| 21 May 2026 | 8-K | 21 May 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 11 May 2026 | 8-K | 11 May 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 28 Oct 2026 | Philotimo Fund, LP | 13G | 5.4% | 2.3M |
| 21 Jul 2026 | ROYCE & ASSOCIATES LP | 13G amended | 7.81% | 3.3M |
| 13 Feb 2026 | Nantahala Capital Management, LLC | 13G amended | 9.99% | 4.1M |
| 20 Jan 2026 | ROYCE & ASSOCIATES LP | 13G amended | 5.95% | 2.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 213.7K | +3.34% | 1.8 |
| 30 Sep 2026 | 206.8K | -5.15% | 1.17 |
| 15 Sep 2026 | 218.0K | +6.26% | 2.46 |
| 31 Aug 2026 | 205.2K | -10.92% | 1.28 |
| 14 Aug 2026 | 230.4K | -13.77% | 1.49 |
| 31 Jul 2026 | 267.1K | +6.15% | 4.69 |
| 15 Jul 2026 | 251.7K | +41.96% | 3.88 |
| 30 Jun 2026 | 177.3K | +26.93% | 1.2 |
Funds that hold it
From each fund's latest Form 13F.
78 funds held it at 30 Jun 2026: 33 added and 22 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Nantahala Capital Management, LLC | 6,540,496 | $29.4M | – |
| Royce & Associates LP | 3,274,064 | $14.7M | +662,840 |
| Archon Capital Management LLC | 2,644,717 | $11.9M | -146,206 |
| Vanguard Capital Management LLC | 1,534,847 | $6.9M | -20,425 |
| Essex Investment Management Co. LLC | 1,136,630 | $5.1M | +235,232 |
| AIGH Capital Management LLC | 1,128,343 | $5.1M | +23,373 |
| Silverberg Bernstein Capital Management LLC | 1,039,641 | $4.7M | -1,429 |
| Commonwealth Equity Services, LLC | 649,061 | $2.9M | 0 |
| Horizon Kinetics Asset Management LLC | 585,000 | $2.6M | -30,000 |
| BlackRock, Inc. | 560,986 | $2.5M | +33,238 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B